Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>Daiwa Raises WUXI BIO (02269.HK) TP to $42, Keeps Buy Rating
Recommend 9 Positive 5 Negative 5 |
||||
|
||||
|
Daiwa released a research report raising its target price for WUXI BIO (02269.HK) from $35.5 to $42, with rating kept at Buy. The broker lifted its 2025-2027 EPS forecasts for WUXI BIO by 1-5%, based on higher project signing expectations and continued operational leverage, and raised its 2028-2032 revenue forecasts by 3-7%, based on higher project growth trajectory. WUXI BIO gained 128 net new projects last year, higher than the broker's forecast of 105, Daiwa added. During the period, there were 209 gross new projects, with half coming from US clients, and two-thirds being bi-/ multi-specific antibodies and ADCs. AASTOCKS Financial News Website: www.aastocks.com |
||||
Copied to Clipboard
 |
||||
